UNSPSC 51385606: Guacetisal

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T6EKB9V2O2, chemically known as benzoic acid, 2-(acetyloxy)-, 2-methoxyphenyl ester but generally known as guacetisal, which bears US NIH Compound Identifier 68749. European Medicines Agency schedules Guacetisal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07968MIG. The term GUACETISAL is an International Non-Proprietary Name.

UNSPSC 51385606 Guacetisal, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The single identified opportunity—Seminole County, Florida's IFB60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023—solicits Naloxone and Safe Drug Deactivation Systems, which fall outside the scope of the code's nominal product classification. The mismatch suggests either a tagging error in the source data or a significant divergence between the code's intended scope and how it has been applied in practice.

The code shows minimal recent activity in state and local procurement. No additional opportunities appear in the source beyond the Seminole County bid, which itself represents a commodity procurement inconsistent with the code's stated purpose. Without a robust set of recent solicitations aligned to the code's actual scope, bid patterns, issuing-body concentration, or geographic clustering cannot be reliably characterized from available data. Firms evaluating pursuit under this code should verify the accuracy of the UNSPSC classification and assess whether opportunities currently tagged to it represent genuine market demand or administrative misclassification.